Tagged with EUROPE

Global The global regulatory landscape for medical cannabis, showing the countries in which medical cannabis and cannabinoid treatments are legal / essentially legal, illegal but often unenforced, decriminalized, and illegal.   Made with Visme Infographic Maker   Click here to download our report on Canada’s world-leading medical cannabis industry

Europe The top spenders on pharma R&D in Europe for 2015 were Switzerland – which spent over EUR 6.5 billion – followed by Germany – which spent EUR 6.2 billion – and the UK – which spent EUR 5.8 billion.

Europe The most valuable pharma markets in Europe for 2015. Germany leads the way, followed by France, Italy and the UK. For more pharma facts and figures, click here.

Poland The value of Poland’s pharmaceutical exports shot from USD 501 million in 2005 to USD 3.475 billion in 2015, a total growth of an astounding 590% and a compound annual growth rate of 21%. Most exports go to Europe (80%) but Asian markets are becoming increasingly important to Poland and…

Poland Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to find a sustainable balance between government and industry to ensure patients receive world-class healthcare. Furthermore, they highlight the importance of…

Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…

Austria Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of Yondelis®, the company’s flagship product. Furthermore, he provides an overview of the clinical trials the Austrian affiliate is undertaking and…

Bulgaria Assena Stoimenova, member of the management board of the European Medicines Agency (EMA) and executive director of the Bulgarian Drug Agency (BDA), explains the Agency’s evolution under her tenure as well as her commitment to ensuring that the BDA remains predictable, transparent and fair, being fully focused on safeguarding patients…

Austria Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and how innovation and drug diversity is being stifled under the current reimbursement system. She also gives insights into Austria´s interaction…

Iceland Jakob Falur Gardarsson, general manager at Frumtök, the Icelandic Association of the Pharmaceutical Industry, highlights access as the main challenge that needs to be met in order to propel Iceland’s healthcare system to the level of other Northern European countries. He also expresses his trust in the willingness of the…

Switzerland Roel Van Doren provides a fascinating insight into the interplay between the life sciences and industrial automation sectors in Europe, whilst also detailing Emerson’s footprint in Switzerland and beyond, as well as the company’s latest innovations. We understand you have been European President at Emerson Automation Solutions since 2012. What…

Switzerland The VP of Medtronic’s Benelux, Central Europe, Greece and Israel cluster highlights the global medtech giant’s efforts to position itself as the partner of choice to tackle prevailing global healthcare challenges. Medtronic is famous for the concept of “value based healthcare”. Medtronic’s global CEO Omar Ishrak recently said that it…